Gene · 965
Papers4,043
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
261 to 280 of 4,043
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Comparative Assessment of the Kinetics of Cellular and Humoral Immune Responses to COVID-19 Vaccination in Cancer Patients. | Viruses | 2023 | 37515127 | PubTator, text mining | PubMed |
| Genetic Basis of Inflammatory Demyelinating Diseases of the Central Nervous System: Multiple Sclerosis and Neuromyelitis Optica Spectrum. | Genes (Basel) | 2023 | 37510224 | PubTator, text mining | PubMed |
| ALK Fusion in an Adolescent with Acute Myeloid Leukemia: A Case Report and Review of the Literature. | Biomedicines | 2023 | 37509482 | PubTator, text mining | PubMed |
| Dissecting the Protective Effect of CD8+ T Cells in Response to SARS-CoV-2 mRNA Vaccination and the Potential Link with Lymph Node CD8+ T Cells. | Biology (Basel) | 2023 | 37508464 | PubTator, text mining | PubMed |
| Autoimmune thyroid disease disrupts immune homeostasis in the endometrium of unexplained infertility women-a single-cell RNA transcriptome study during the implantation window. | Front Endocrinol (Lausanne) | 2023 | 37501789 | PubTator, text mining | PubMed |
| Analysis of intercellular communication in the osteosarcoma microenvironment based on single cell sequencing data. | J Bone Oncol | 2023 | 37501717 | PubTator, text mining | PubMed |
| Secretome-based acellular therapy of bone marrow-derived mesenchymal stem cells in degenerative and immunological disorders: A narrative review. | Heliyon | 2023 | 37496898 | PubTator, text mining | PubMed |
| Population dynamics of immunological synapse formation induced by bispecific T cell engagers predict clinical pharmacodynamics and treatment resistance. | Elife | 2023 | 37490053 | PubTator, text mining | PubMed |
| Detection of Antibody-Dependent Cell-Mediated Cytotoxicity-Supporting Antibodies by NK-92-CD16A Cell Externalization of CD107a: Recognition of Antibody Afucosylation and Assay Optimization. | Antibodies (Basel) | 2023 | 37489366 | PubTator, text mining | PubMed |
| Diabetic complications and prospective immunotherapy. | Front Immunol | 2023 | 37483613 | PubTator, text mining | PubMed |
| HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy. | Front Immunol | 2023 | 37483605 | PubTator, text mining | PubMed |
| Insights into immuno-oncology drug development landscape with focus on bone metastasis. | Front Immunol | 2023 | 37475868 | PubTator, text mining | PubMed |
| T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions. | Front Oncol | 2023 | 37465110 | PubTator, text mining | PubMed |
Comparison of recent updates in genetics, immunology, biomarkers, and neuroimaging of primary-progressive and relapsing-remitting multiple sclerosis and the role of ocrelizumab in the management of their refractory cases. | Health Sci Rep | 2023 | 37448727 | PubTator, text mining | PubMed |
| Strategies to improve γδTCRs engineered T-cell therapies for the treatment of solid malignancies. | Front Immunol | 2023 | 37441064 | PubTator, text mining | PubMed |
| Differential expression profile of genes involved in the immune response associated to progression of chronic Chagas disease. | PLoS Negl Trop Dis | 2023 | 37440604 | PubTator, text mining | PubMed |
| Pathology and new insights in central nervous system lymphomas. | Curr Opin Oncol | 2023 | 37439536 | PubTator, text mining | PubMed |
| How molecular advances may improve the diagnosis and management of PTCL patients. | Front Oncol | 2023 | 37427095 | PubTator, text mining | PubMed |
| Favorable outcome of PML-RARα short isoform and FLT3-ITD mutation in a patient with several adverse prognostic markers: A case report. | Clin Case Rep | 2023 | 37426684 | PubTator, text mining | PubMed |
| Breaking down the tumor immune infiltration within pediatric sarcomas. | Front Endocrinol (Lausanne) | 2023 | 37424864 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/965/papers?page=14